HCM

NEUTRAL

$15.24 Live

HUTCHMED (China) Limited · NASDAQ

Target $22.85 (+50.0%)

$12.98 52W Range $19.5

HCM HUTCHMED (China) Limited - Fundamental Analysis

NEUTRAL

Console Chart News

HCM Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Drug Manufacturers - Specialty & Generic

Current Price Live

$15.24

Analyst Target

$22.85

+50.0% Upside

52W High

$19.5

52W Low

$12.98

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 11, 2026

Market cap

$2.62B

P/E

5.75

ROE

45.2%

Profit margin

83.3%

Debt/Equity

0.08

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

80%

HCM presents a contradictory profile: it is fundamentally undervalued based on deterministic metrics, with a Piotroski F-Score of 5/9 (Stable) and a current price ($15.24) well below both its Graham Number ($20.72) and Intrinsic Value ($18.55). However, the company's operational health is concerning, characterized by negative revenue growth (-16.5%) and a severe collapse in earnings (-98.1% YoY). While the balance sheet is exceptionally strong with very low debt and high liquidity, the core business is currently unprofitable at the operating level. The investment case relies on a turnaround or a catalyst to realize the analyst target price of $22.85.

Key Strengths

Strong liquidity with a Current Ratio of 4.96

Very low leverage (Debt/Equity of 0.08)

Trading at a significant discount to Graham Number ($20.72)

Low trailing P/E ratio of 5.75

Positive 1-year price performance (+21.6%)

Key Risks

Severe earnings contraction (-98.1% YoY)

Negative operating margin (-13.16%) indicating core business losses

Declining revenue growth (-16.5% YoY)

Bearish technical trend (0/100 score)

High discrepancy between net profit margin and operating margin suggesting non-core gains

AI Fair Value Estimate

Based on comprehensive analysis

$18.2

+19.4% above current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Moderate

Value

Future

Past

Health

Dividend

AI Verdict

Speculative Value Play

Key drivers: Strong balance sheet, Deep valuation discount, Poor operational growth, Negative operating cash flow profile

Confidence

85%

Value

85/100

Ref P/E 5.75, Graham Number $20.72

Positives

Price below Graham Number
Price below Intrinsic Value
Low trailing P/E

Watchpoints

Forward P/E (29.34) is significantly higher than trailing P/E, suggesting expected earnings drop

Future

20/100

Ref Growth rates

Positives

Analyst target price suggests 50% upside

Watchpoints

Revenue growth -16.5%
Earnings growth -98.1%

Past

30/100

Ref Historical trends

Positives

Recent 1Y recovery

Watchpoints

5Y change of -48%
Consistent history of earnings misses/volatility

Health

75/100

Ref Piotroski F-Score, Debt/Equity

Positives

Piotroski F-Score 5/9 (Stable)
Debt/Equity 0.08
Current Ratio 4.96

Watchpoints

Negative ROA (-1.62%)

Dividend

0/100

Ref Yield, Payout

Positives

No standout positives identified.

Watchpoints

No dividend payments
0/100 strength score

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$15.24

Analyst Target

$22.85

Upside/Downside

+50.0%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for HCM and closest competitors.

Updated 2026-04-10

Company	5Y	3Y	1Y	6M	1M	1W
HCM HUTCHMED (China) Limited Primary	-48.0%	-1.7%	+21.6%	+1.1%	+4.6%	-1.2%
APLS Apellis Pharmaceuticals, Inc. Peer	-59.8%	-70.9%	-22.3%	-23.8%	-15.1%	-5.6%
ARQT Arcutis Biotherapeutics, Inc. Peer	-30.1%	+98.3%	+53.6%	+31.6%	-14.4%	-5.2%
ATEC Alphatec Holdings, Inc. Peer	+4.7%	+20.4%	+33.9%	+44.4%	-24.8%	-11.9%
HTFL Heartflow, Inc. Peer	-10.1%	-10.1%	-10.1%	-19.5%	+21.3%	+8.5%

HCM

HUTCHMED (China) Limited

Primary

-48.0%

-1.7%

+21.6%

+1.1%

+4.6%

-1.2%

APL

Apellis Pharmaceuticals, Inc.

Peer

-59.8%

-70.9%

-22.3%

-23.8%

-15.1%

-5.6%

ARQ

Arcutis Biotherapeutics, Inc.

Peer

-30.1%

+98.3%

+53.6%

+31.6%

-14.4%

-5.2%

ATE

Alphatec Holdings, Inc.

Peer

+4.7%

+20.4%

+33.9%

+44.4%

-24.8%

-11.9%

HTF

Heartflow, Inc.

Peer

-10.1%

-19.5%

+21.3%

+8.5%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

5.75

29.34

N/A

2.12

4.78

21.59

-458.18

$2.62B

Profitability

Profit margins and return metrics

Profit Margin 83.3%

Operating Margin -13.16%

Gross Margin 11.64%

ROE 45.25%

ROA -1.62%

Growth

Revenue and earnings growth rates

Revenue Growth -16.5%

Earnings Growth -98.1%

Q/Q Revenue Growth N/A

Q/Q Earnings Growth -83.6%

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.08

Low debt

Current Ratio

4.96

Strong

Quick Ratio

4.81

Excellent

Cash/Share

$1.59

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Total Assets

$1.8B

Liabilities

$0.5B

Equity

$1.2B

Debt/Equity

0.41x

Quarterly Earnings History

EPS performance vs analyst estimates

2026-07-30

$N/A

2022-03-02

$-0.03

+77.5% surprise

2021-07-28

$-0.4

-477.9% surprise

2021-06-21

$-0.3

+18.9% surprise

Healthcare Sector Comparison

Comparing HCM against 226 companies in the Healthcare sector (19 bullish, 76 neutral, 131 bearish)

P/E Ratio

5.75

This Stock

45.29

Sector Avg

-87.3% (Discount)

Return on Equity (ROE)

45.25%

This Stock

-40.43%

Sector Avg

-211.9% (Below Avg)

Profit Margin

83.3%

This Stock

-18.65%

Sector Avg

-546.7% (Weaker)

Debt to Equity

0.08

This Stock

4.61

Sector Avg

-98.3% (Less Debt)

Revenue Growth

-16.5%

This Stock

97.21%

Sector Avg

-117.0% (Slower)

Current Ratio

4.96

This Stock

3.51

Sector Avg

+41.4% (Stronger)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
HCM HUTCHMED (China) Limited	NEUTRAL	$2.62B	5.75	45.2%	83.3%	$15.24
APLS Apellis Pharmaceuticals, Inc.	BEARISH	$2.42B	105.22	7.5%	2.2%	$18.94	Compare
ARQT Arcutis Biotherapeutics, Inc.	BEARISH	$2.82B	-	-9.3%	-4.3%	$22.75	Compare
ATEC Alphatec Holdings, Inc.	BEARISH	$2.32B	-	-540.4%	-21.3%	$15.62	Compare
HTFL Heartflow, Inc.	BEARISH	$2.31B	-	-111.4%	-66.3%	$26.95	Compare

HCM HUTCHMED (China) Limited

NEUTRAL

Mkt Cap

$2.6B

P/E

5.8

ROE

45.2%

Price

$15.24

Compare with HCM

Compare with HCM

ATEC Alphatec Holdings, Inc.

Compare with HCM

Compare with HCM

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

NONE

15 analysts

B of A Securities

2026-03-10

Maintains

Buy Buy

Past News Coverage

Recent headlines mentioning HCM from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

HCM

HCM HUTCHMED (China) Limited - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!